PREX-1979: Modeling the first ever prototype of a new generation of microbicides for preventing HIV infection among high risk women

African Journal of Biotechnology

Volumn 6, Issue 10, 2007, Pages 1221-1224

  Misaki, Wayengera ^a  

^a Restrizymes Corporation   (Canada)

Author keywords

Combination microbicides; HIV genomes; HIV AIDS; Novel microbicides strategies; Restriction modification systems

Indexed keywords

MICROBICIDE; PREX 1979; UNCLASSIFIED DRUG;

ARTICLE; GENOME ANALYSIS; HIGH RISK POPULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; SEXUALLY TRANSMITTED DISEASE; VIRUS ENVELOPE; VIRUS GENOME; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 34249830147     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Anastasopoulo KG, Marozsan AJ, Matet A, Snyder AD, Arts EJ, Kuhmann SE, Moore JP (2006). Variants of differing replication capacity (fitness) co-exist in the quasispecies populations of viruses resistant to a small molecule CCR5 inhibitor. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract WEPE0005.
2. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F (2001). Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 15: 1369-1377.
3. Bartlett JA, Fath MJ, DeMasi R (2001). An updated systematic overview of triple combination therapy in antiretroviral-naive HIVinfected adults. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. AIDS. In press.
4. Bax R, Douville K, McCormick D, Rosenberg M, Higgins J, Bowden M (2006). Microbicides - evaluating multiple formulations of C31G. Contraception 66: 365-368.
5. CDC. Pneumocystis pneumonia- Los Angeles. MMWR (1981). 30: 250-252.
6. Dhawan D, Mayer KH (2006). Microbicides to Prevent HIV Transmission: Overcoming Obstacles to Chemical Barrier Protection JID; 193: 36-44.
7. Davison DK, Medinas RJ, Mosier SM, Bowling TS, Delmedico MK, Dwyer JJ, Cammack N, Greenberg ML (2006). New fusion inhibitor peptides, TRI-999 and TRI-1144, are potent inhibitors of enfuvirtide and T-1249 resistant isolates. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract THPE0021.
8. Delmedico M, Bray B, Cammack N, Di J, Heilman D, Silinski P, Webb S, Wring S, Greenberg M (2006). Next generation fusion inhibitor candidates TRI-1144 and TRI-999 have improved pharmacokinetics: progress toward once/week dosing. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract THAA0303.
9. Department of Health and Human Services.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. May 4, 2006. Available at: http://aidsinfo.nih.gov/guidelines/GuidelineDetail.aspx?MenuItem= Gui delines&Search= Off&GuidelineID=7&ClassID=1.
10. Green EC (2002). "What happened in Uganda?" [Powerpoint presentation]; "What are the lessons from Uganda for AIDS prevention? [10-page document]. Presentation to USAID, Washing-ton DC.
11. Fanci AS (1999). The AIDS epidemic Considerations for the 21st century, N. Engl. J. Med. 341: 1046-1050.
12. Global HIV prevention working group (2006). New Approaches to HIV prevention: Accelerating research and ensuring future access. Executive summary, IAS.
13. Gulick R, Su Z, Flexner C, Hughes M, Skolnik P, Godfrey C, Greaves W, Wilkin T, Gross R, Coakley E, Zolopa A, Hirsch M, Kuritzkes D (2006). ACTG 5211: phase II study of the safety and efficacy of vicriviroc in HIV-infected treatmentexperienced subjects. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada.Abstract THLB0217.
14. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA (2006). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society.USA Panel. JAMA. 296: 827-843.
15. HIV gene sequence Database. www.hiv.lanl.gov/content/hivdb/ALIGN_CURRENT/ ALIGN-INDEX.html
16. HIV Vaccines and Microbicides Resource Tracking Working Group. Tracking funding for microbicide research and development: estimates of annual investments 2000 to 2005. Geneva: Joint United Nations Programme on HIV/AIDS, 2005. Available at: http://www.unaids.org/html/pub/una-docs/ microbicidestrackingfunding_aug05_en_pdf.pdf.
17. Stover J (2002). "The effects of behavior change on trends in HIV incidence in Uganda and Kenya" [Powerpoint Presentation]. Presentation to USAID, Washington DC.
18. Joint UNAIDS/WHO. Report on the global HIV/AIDS epidemic. Fact sheet. Geneva; UNAIDS/WHO 1997.
19. Markowitz M, Nguyen B-Y, Gotuzzo F, Mendo F, Ratanasuwan W, Kovacs C, Zhao J, Gilde L, Isaacs R, Teppler H (2006). Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part ofcombination ART in treatment-naive HIV-1 infected patients. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract THLB0214.
20. Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, Bax R (2004). A randomized phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Contraception 70: 233-240.
21. Mayer H, van der Ryst E, Saag M, Clotet B, Fatkenheuer G, Clumeck N, Turner K, Goodrich JM (2006). Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with a dual/mixed-tropic HIV-1:24-week results of a phase 2b exploratory trial. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract THLB0215.
22. Nantulya VM (2002). "HIV/AIDS prevention: Policy and pro-gram context of Uganda's success story" [Powerpoint presentation]. Presentation to USAID, Washington DC.
23. Norris D, Morales J, Godofsky E, Garcia F, Hardwicke R, Lewis S (2005). TNX-355 in combination with optimized background regimen (OBR) exhibits greater antiviral activity than OBR alone in HIV treatment experienced patients. Program and abstracts of the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy; Washington, DC. Abstract LB2-26.
24. Norris D, Morales J, Godofsky E, Garcia F, Hardwicke R, Lewis S (2006). TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase II study at 48 weeks. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract THLB0218.
25. Patton DL, Sweeney YT, Balkus JE, Hillier SL (2006). Vaginal and rectal topical microbicide development: safety and efficacy of 1.0% Savvy (C31G) in the pigtailed macaque. Sex Transm Dis. 33(11): 691-695.
26. Pugach P, Kuhmann S, Ketas T, Moore JP (2006). The mechanisms of HIV-1 escape from small molecule CCR5 antagonists. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract MOAA0105.
27. Stoneburner R, Low-Beer D, Barnett T, Whiteside A (2002). Enhancing HIV prevention in Africa: Investigating the role of social cohesion on knowledge diffusion and behavior change in Uganda." Presentation at the World AIDS Conference, Durban, South Africa, July 2000; also presented at the World Bank, October 2000, and at USAID, Washington DC.
28. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL (1998). A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339: 504-510.
29. Sansone A, Keung A, Tetteh E, Weisbrot H, Martinho M, Lang S, Post D, Keller R, Kraan M (2006). Vicriviroc (VCV) pharma-cokinetics (PK): lack of impact of ritonavir (RTV)-boosted protease inhibitors (PI). Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract TUPE0074.
30. UNAIDS. Report on the global HIV-AIDS epidemic July 2004.
31. UNAIDS. Report on the global HIV-AIDS epidemic July 2006.
32. Web cutter Version 2.0. http://rna.lundberg.gu.se/cutter2/
33. WHO. Removing obstacles to health development. Geneva; WHO: 1999.